

### IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method of ~~stimulating a HIV1-specific CD8<sup>+</sup> response in a human infected with an HIV retrovirus~~ said method comprising:

administering to ~~the~~ a human, an attenuated recombinant NYVAC, ALVAC or MVA pox virus, which enters the cells of the human and intracellularly produces HIV specific peptides for presentation on the cell's MHC class I molecules,

where said peptides are presented in an amount sufficient to stimulate HIV antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> proliferative responses, and

where said human is infected with an HIV1 retrovirus and

i. has a viral load of less than 10,000 viral copies per ml of plasma and a CD4<sup>+</sup> cell count of above 500 cells/ml, and

ii. has been treated with one or more anti-viral agents, which contributed to a lower viral copy and higher CD4<sup>+</sup> cell count than before treatment

where said HIV specific peptides consist of ~~comprise~~ HIV Gag, ~~Gp120, Nef or Pol or Env~~ peptides.

2. (Previously Presented) A method of claim 1 wherein the human has been treated with anti-viral agents, which resulted in the human having a viral load of less than 1,000 viral copies per ml of blood serum and a CD4<sup>+</sup> cell count of above 500 cells/ml.

3. (Currently Amended) A method of claim 1[2] wherein the anti-viral agents comprise a combination of protease inhibitors and inhibitors of reverse transcriptase.

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Previously Presented) A method of claim 1 where the attenuated recombinant pox virus is administered a second time.

10. (Canceled)

11. (Canceled)

12. (Previously Presented) A method of claim 1 wherein the method further comprises administering an adjuvant.

13. (Original) A method of claim 1 further comprising administering interleukin 2 or CD40 ligand in an amount sufficient to potentiate the CD8<sup>+</sup> response.

14. (Previously Presented) A method of claim 1 where the human has been infected with HIV and has demonstrated repeated and sustained proliferative T-cell responses to Gp120 envelope protein.

15. (Previously Presented) A method of claim 14 where the human has demonstrated repeated and sustained proliferative T-cell responses to p24 Gag antigen.

16. (Previously Presented) A method of claim 1 where the human is infected with HIV and is further tested by a skin test for a hypersensitive response to p24 Gag antigen.

17. (Previously Presented) A method of claim 1 where the human is infected with HIV and is further tested by a skin test for a hypersensitive response to Gp120 envelope antigen.

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Currently Amended) The method of claim 1 [2], wherein anti-viral treatment is reduced or stopped after administering the recombinant virus.

22. (Currently Amended) The method of claim 1 [2], wherein anti-viral treatment is interrupted after administering the recombinant virus.